Overview
SMMT market data
Price History
SMMT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.31 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.25 – $30.98 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $10.2K · P/B 19.76 · P/S 10,636.66.
Company News
Alpha Buying: When a CEO Spends $5 Million on His Own Stock, Pay AttentionBenzinga · Jul 24, 2026, 7:29 PM
Summit Therapeutics Flags Going Concern Risk Over Cash NeedsBenzinga · Jul 24, 2026, 3:53 PM
Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38Benzinga · Jul 24, 2026, 2:46 PM
Guggenheim Maintains Buy on Summit Therapeutics, Lowers Price Target to $38Benzinga · Jul 24, 2026, 1:52 PM
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · Jul 24, 2026, 12:04 PM
Summit Therapeutics shares are trading lower after the company reported Q2 financial results and disclosed it does not have sufficient working capital to fund planned operations for the next twelve months.Benzinga · Jul 24, 2026, 11:45 AM
Summit Therapeutics Plans To Offer $380M Common SharesBenzinga · Jul 23, 2026, 8:39 PM
8-K filing — Summit Therapeutics Inc. (SMMT)SEC EDGAR · Jul 23, 2026, 8:34 PM
Summit Therapeutics Raises Going Concern Doubt, Says Current Cash Is Insufficient To Fund Operations For The Next 12 MonthsBenzinga · Jul 23, 2026, 8:25 PM
Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) EstimateBenzinga · Jul 23, 2026, 8:09 PM